Investment Rating - The report maintains a rating of "Buy" for the company with a target price of RMB 39.00 [6][7]. Core Insights - The company reported a revenue of RMB 1.318 billion for 2024, representing a year-on-year growth of 27.61%, and a net profit attributable to the parent company of RMB 300 million, up 32.8% year-on-year. In Q4, the revenue was RMB 281 million, with a quarter-on-quarter increase of 34.01% but a year-on-year decrease of 4.37%. For Q1 2025, the revenue reached RMB 240 million, showing a year-on-year increase of 44.0%, and the net profit was RMB 44.2 million, up 24.6% year-on-year [1][4]. Revenue Performance - In 2024, the revenue from mosquito repellent, baby care, and essential oil series was RMB 439 million (up 35.4% YoY), RMB 690 million (up 32.4% YoY), and RMB 158 million (up 7.9% YoY) respectively. In Q1 2025, the revenue from these series was RMB 43 million (up 10.5% YoY), RMB 179 million (up 65.6% YoY), and RMB 11 million (down 6.1% YoY) respectively [2]. Channel Performance - In 2024, the online direct sales revenue was RMB 774 million (up 24.8% YoY), while non-platform distribution revenue was RMB 347 million (up 39.6% YoY) with a gross margin of 48.9%. The company plans to expand its mosquito repellent series into offline channels, which is expected to continue the strong performance of non-platform distribution [3]. Profit Forecast and Valuation - The company’s net profit forecasts for 2025, 2026, and 2027 are RMB 406 million, RMB 505 million, and RMB 625 million respectively, with corresponding EPS of RMB 1.00, RMB 1.25, and RMB 1.54. The report assigns a PE ratio of 39 for 2025, raising the target price to RMB 39.00 from the previous RMB 30.00 [4][12].

Investment Rating - The report maintains a "Recommended" investment rating for Runben Co., Ltd. (603193.SH) [1][8] Core Viewpoints - The company is expected to achieve a revenue of 1.318 billion yuan in 2024, representing a year-on-year growth of 27.61%, with a net profit of 300 million yuan, up 32.8% [4] - The growth in revenue is driven by the mosquito repellent business, which is projected to grow by 35.39% to 439 million yuan, and the baby care series, which is expected to generate 690 million yuan in revenue, a year-on-year increase of 32.42% [5] - The company plans to launch over 90 new products in 2024, demonstrating its commitment to innovation and responsiveness to market demands [5] Financial Summary - The total market capitalization of the company is 14.1 billion yuan, with a total share capital of 405 million shares [1] - The company’s gross margin for 2024 is projected to be 58.17%, an increase of 1.83 percentage points, while the net margin is expected to be 22.77%, up 0.89 percentage points [4] - The company’s online sales are anticipated to reach 970 million yuan in 2024, reflecting a year-on-year growth of 23.80% [5] - The projected earnings per share (EPS) for 2024 is 0.74 yuan, with a price-to-earnings (P/E) ratio of 47.0 [7]

Core Viewpoint - Runben Co., Ltd. has shown significant growth in revenue and net profit in 2024, driven by an accelerated pace of new product launches, although it faces challenges with high marketing expenses and reliance on online sales channels [2][3][5]. Financial Performance - In 2024, Runben achieved an operating revenue of 1.318 billion yuan, representing a year-on-year increase of 27.61%, and a net profit attributable to shareholders of 300 million yuan, up 32.80% [3]. - Sales expenses reached 380 million yuan, growing by 41.25%, which is significantly higher than the revenue growth rate [3]. Product Segmentation - Revenue from mosquito repellent products, baby care products, and essential oil products was 439 million yuan, 690 million yuan, and 158 million yuan, respectively [4]. - The proportion of revenue from baby care products has increased, surpassing 52% in 2024, indicating a strategic shift from mosquito repellent products [6]. Sales Channels - Online sales accounted for over 73% of total sales, amounting to 970 million yuan, highlighting the company's heavy reliance on e-commerce platforms [5]. - Runben is actively developing offline channels, partnering with key accounts such as Walmart and other retail chains, although contributions from these channels remain relatively weak [5]. Market Competition - The baby care market is highly competitive, with established domestic brands and foreign players vying for market share, making it challenging for Runben to establish a strong foothold [6][7]. - Runben's market share in the baby care segment is approximately 2.5%, ranking sixth among competitors, which include well-known brands like Johnson & Johnson and Pigeon [8]. Brand Strategy - Runben operates under a single brand, which limits its ability to diversify and strengthen its market presence compared to competitors with multiple brands [7]. - The company’s strategy to leverage its existing customer base from mosquito repellent products to enter the baby care market may face difficulties due to the intense competition and market dynamics [6][8].

申万宏源证券承销保荐有限责任公司 关于润本生物技术股份有限公司 2024年持续督导年度报告书 | 保荐人 | 申万宏源证券承销保荐 有限责任公司 | 上市公司简称 | 润本股份 | | --- | --- | --- | --- | | 保荐代表人 | 张晓、刘令 | 上市公司代码 | 603193 | | 报告年度 | 2024年度 | 报告日期 | 2025年4月25日 | 经中国证券监督管理委员会《关于同意润本生物技术股份有限公司首次公开 发行股票注册的批复》（证监许可〔2023〕1631号）核准，润本生物技术股份有 限公司（以下简称"润本股份"或"公司"）首次向社会公开发行人民币普通股 （A股）60,690,000股，每股发行价格为17.38元/股，募集资金总额为105,479.22 万元，实际募集资金净额为97,122.85万元。上述募集资金已于2023年10月11日全 部到账，容诚会计师事务所（特殊普通合伙）对公司本次首次公开发行股票的资 金到位情况进行了审验，并出具了《验资报告》（[2023]510Z0017号）。 申万宏源证券承销保荐有限责任公司（以下简称"申万宏源承销保荐"、"保 荐人"）作 ...

申万宏源证券承销保荐有限责任公司 关于润本生物技术股份有限公司 2025 年度 使用闲置自有资金进行现金管理的核查意见 公司及子公司拟使用不超过人民币 10 亿元的闲置自有资金购买理财产品。 在上述额度内，资金可循环滚动使用。 （三）资金来源 公司及子公司本次购买理财产品的资金来源系暂时闲置的自有资金。 （四）投资方式 公司及子公司将按照相关规定严格控制风险，使用闲置自有资金投资的产品 品种为安全性高、流动性好、风险等级较低的投资产品。 申万宏源证券承销保荐有限责任公司（以下简称"申万宏源承销保荐"、"保 荐人"）作为润本生物技术股份有限公司（以下简称"润本股份"、"公司"）持续 督导工作的保荐人，根据《证券发行上市保荐业务管理办法》《上海证券交易所 上市公司自律监管指引第 1 号——规范运作》《上海证券交易所上市公司自律监 管指引第 11 号——持续督导》等相关规定，对润本股份使用闲置自有资金进行 现金管理的事项进行了核查，具体情况如下： 一、投资情况概述 （一）投资目的 为提高公司资金使用效率，合理利用闲置自有资金，增加资金收益，在确保 资金安全性、流动性且不影响公司正常经营的基础上，公司及下属子公司拟使 ...

申万宏源证券承销保荐有限责任公司 关于润本生物技术股份有限公司 部分募投项目延期的核查意见 申万宏源证券承销保荐有限责任公司（以下简称"申万宏源承销保荐"、"保 荐人"）作为润本生物技术股份有限公司（以下简称"润本股份"、"公司"）持续 督导工作的保荐人，根据《上市公司监管指引第 2 号——上市公司募集资金管理 和使用的监管要求》《上海证券交易所股票上市规则》以及《上海证券交易所上 市公司自律监管指引第 1 号——规范运作》等规定，对润本股份首次公开发行股 票部分募投项目延期的情况进行了核查，具体如下： 一、募集资金基本情况 经中国证券监督管理委员会出具的《关于同意润本生物技术股份有限公司首 次公开发行股票注册的批复》（证监许可[2023]1631 号），公司于 2023 年 9 月 27 日首次公开发行人民币普通股（A 股）60,690,000 股，发行价格为人民币 17.38 元/股，募集资金总额为人民币 1,054,792,200.00 元，扣除不含税的发行费用人民 币 83,563,748.31 元，实际募集资金净额为人民币 971,228,451.69 元。 上述募集资金已于 2023 年 10 月 ...

报告正文……………………………………………………1-2 内部控制审计报告 司农审字 [2025]24009540035 号 润本生物技术股份有限公司全体股东： 按照《企业内部控制审计指引》及中国注册会计师执业准则的相关要求，我们 审计了润本生物技术股份有限公司（以下简称"润本股份"）2024 年 12 月 31 日的财 务报告内部控制的有效性。 润本生物技术股份有限公司 内部控制审计报告 司农审字[2025]24009540035 号 目 录 我们认为，润本股份于 2024 年 12 月 31 日按照《企业内部控制基本规范》和 相关规定在所有重大方面保持了有效的财务报告内部控制。 1 （此页无正文，为润本股份司农审字[2025]24009540035 号内部控制审计报告 之签字盖章页。） 一、企业对内部控制的责任 按照《企业内部控制基本规范》、《企业内部控制应用指引》、《企业内部控 制评价指引》的规定，建立健全和有效实施内部控制，并评价其有效性是润本股份 董事会的责任。 二、注册会计师的责任 我们的责任是在实施审计工作的基础上，对财务报告内部控制的有效性发表审 计意见，并对注意到的非财务报告内部控制的重大缺陷 ...

润本生物技术股份有限公司 2024 年度审计报告 司农审字[2025]24009540015 号 | 目 录 | | | --- | --- | | 审计报告……………………………………………… | 1-5 | | 合并资产负债表……………………………………… | 1 | | 合并利润表…………………………………………… | 2 | | 合并现金流量表……………………………………… | 3 | | 合并所有者权益变动表……………………………… | 4-5 | | 母公司资产负债表…………………………………… | 6 | | 母公司利润表………………………………………… | 7 | | 母公司现金流量表…………………………………… | 8 | | 母公司所有者权益变动表…………………………… | 9-10 | | 财务报表附注………………………………………… | 11-93 | 审 计 报 告 司农审字[2025]24009540015 号 润本生物技术股份有限公司全体股东: 一、审计意见 我们审计了润本生物技术股份有限公司（以下简称"润本股份"）财务报表，包 括 2024 年 12 月 31 日的合并及母公司 ...

Investment Rating - The investment rating for the company is "Buy" [1] Core Insights - The company reported strong financial performance with a revenue of 1.318 billion and a net profit of 300 million for 2024, reflecting year-on-year growth of 27.61% and 32.80% respectively [2] - The company is focusing on expanding its product line and enhancing offline presence, with significant growth in both online and offline sales channels [3][4] - The gross margin and net margin showed improvements, indicating better profitability despite rising sales and financial expenses [5] - The company is expected to maintain strong growth in revenue and earnings per share over the next few years, with projections of 1.694 billion in revenue and 389 million in net profit for 2025 [6][7] Financial Performance Summary - In 2024, the company achieved a revenue of 1.318 billion, with a year-on-year growth of 27.6%, and a net profit of 300 million, with a year-on-year growth of 32.8% [9] - The gross margin for 2024 was 58.2%, an increase of 1.82 percentage points year-on-year, while the net margin was 22.8% [9] - The company plans to distribute a cash dividend of 2.3 yuan per 10 shares, totaling 166 million for 2024, with a payout ratio of 55.26% [2] Revenue Breakdown - In 2024, the revenue from different product categories was as follows: mosquito repellent (439 million), baby care (690 million), and essential oils (158 million), with respective year-on-year growth rates of 35.39%, 32.42%, and 7.88% [3] - Online and offline revenues for 2024 were 970 million and 347 million respectively, showing year-on-year growth of 23.10% and 39.66% [4] Profitability Analysis - The company’s gross margin for Q1 2025 was 57.67%, reflecting a year-on-year increase of 1.98 percentage points, while the net margin was 18.41% [5] - The increase in gross margin is attributed to rising product prices and the high-margin baby care segment [5] Future Projections - The company is projected to achieve revenues of 1.694 billion, 2.158 billion, and 2.730 billion for 2025, 2026, and 2027 respectively, with corresponding earnings per share of 0.96, 1.21, and 1.52 [7][9]

润本生物技术股份有限公司 独立董事独立性自查报告 润本生物技术股份有限公司 董事会对独立董事独立性自查情况的专项报告 根据《上市公司独立董事管理办法》《上海证券交易所股票上市规则》《上 海证券交易所上市公司自律监管指引第 1 号——规范运作》等要求，润本生物技 术股份有限公司（以下简称"公司"）董事会，就公司在职独立董事赵晓明先生、 郑怡玲女士的独立性情况进行评估并出具如下专项意见： 润本生物技术股份有限公司董事会 2025 年 4 月 25 日 1 经核查独立董事赵晓明先生、郑怡玲女士的任职经历以及其签署的相关自查 文件，上述人员未在公司担任除独立董事以外的任何职务，也未在公司主要股东 单位担任任何职务，与公司以及主要股东之间不存在利害关系或其他可能妨碍其 进行独立客观判断的关系，符合《上市公司独立董事管理办法》《上海证券交易 所股票上市规则》《上海证券交易所上市公司自律监管指引第 1 号——规范运作》 中对独立董事独立性的相关要求。 ...